IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Interferon-a Combined with Lamivudine versus Lamivudine Monotherapy for the Emergence of YMDD Mutations in Chronic Hepatitis B Infection: A Meta-Analysis of Randomized Controlled Trials
Zhang, Ya-li; Zhang, Jie; Cui, Li-yan
关键词Hepatitis B Lamivudine Interferon YMDD mutations Meta-analysis
刊名HEPATO-GASTROENTEROLOGY
2015
DOI10.5754/hge14871
62期:137页:133-139
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology ; Surgery
研究领域[WOS]Gastroenterology & Hepatology ; Surgery
关键词[WOS]E-ANTIGEN SEROCONVERSION ; COMBINATION THERAPY ; LONG-TERM ; ALPHA-INTERFERON ; SEQUENTIAL TREATMENT ; CHINESE PATIENTS ; VIRUS ; SUPPRESSION ; POLYMERASE ; RESISTANCE
英文摘要

Background/Aims: Tyrosine-methionine-aspartate-aspartate (YMDD) mutations were the main limitation of lamivudine (LAM) for treating chronic hepatitis B (CHB). The aim of this study was to evaluate whether LAM combined with IFN-alpha offer advantage over lamivudine monotherapy for the occurrence of YMDD mutations in CHB using a meta-analysis. Methodology: We searched electronic databases and calculated the odds ratios (OR) with their 95% confidence intervals (CI) and pooled the results. Results: Our meta-analysis indicated that the difference of YMDD mutation rates between the combination therapy of IFN-alpha 2b, IFN-alpha 2a and Peg-IFN-alpha 2a respectively plus LAM and LAM monotherapy (95 % CI, 3.25 - 9.70, 95 % CI, 5.7717.51, 95 % CI, 6.79-26.13, respectively). The rate of YMDD mutations in LAM monotherapy was increased when compared with combination and sequential combination group (95 % CI, 6.79-22.16, and 95 % CI, 2.69-7.75, respectively). The YMDD mutation rate in combination therapy was lower than that of LAM monotherapy in HBeAg positive patients (95 % CI, 4.98-13.23). Conclusions: Our present meta-analysis suggests that different types of IFN-a in combination with LAM can significantly reduce the rate of YMDD mutation compared to LAM monotherapy.

语种英语
WOS记录号WOS:000352115700027
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61870
专题北京大学第三临床医学院
北京大学医学部管理机构_医学部
北京大学第三临床医学院_检验科
作者单位Peking Univ, Hosp 3, Dept Lab Med, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Ya-li,Zhang, Jie,Cui, Li-yan. Interferon-a Combined with Lamivudine versus Lamivudine Monotherapy for the Emergence of YMDD Mutations in Chronic Hepatitis B Infection: A Meta-Analysis of Randomized Controlled Trials[J]. HEPATO-GASTROENTEROLOGY,2015,62(137):133-139.
APA Zhang, Ya-li,Zhang, Jie,&Cui, Li-yan.(2015).Interferon-a Combined with Lamivudine versus Lamivudine Monotherapy for the Emergence of YMDD Mutations in Chronic Hepatitis B Infection: A Meta-Analysis of Randomized Controlled Trials.HEPATO-GASTROENTEROLOGY,62(137),133-139.
MLA Zhang, Ya-li,et al."Interferon-a Combined with Lamivudine versus Lamivudine Monotherapy for the Emergence of YMDD Mutations in Chronic Hepatitis B Infection: A Meta-Analysis of Randomized Controlled Trials".HEPATO-GASTROENTEROLOGY 62.137(2015):133-139.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Ya-li]的文章
[Zhang, Jie]的文章
[Cui, Li-yan]的文章
百度学术
百度学术中相似的文章
[Zhang, Ya-li]的文章
[Zhang, Jie]的文章
[Cui, Li-yan]的文章
必应学术
必应学术中相似的文章
[Zhang, Ya-li]的文章
[Zhang, Jie]的文章
[Cui, Li-yan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。